Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Cluster-Randomized Study to Examine National Characteristics and Outcome Measures of GERD Patients Utilizing the PPI Acid Suppression Symptom (PASS) Test for Response [EncomPASS].

NCT00392002 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00392002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00392002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Cluster-Randomized Study to Examine National Characteristics and Outcome Measures of GERD Patients Utilizing the PPI Acid Suppression Symptom (PASS) Test for Response [EncomPASS].
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2005
Completion date
May 31, 2007
Enrollment
2,000
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux